Business Wire

Brain Corp Continues European Growth, Demonstrates ‘Inventory Scan’ Technology with Tennant Company, a First-of-its-kind Robotic Solution for Automated Analytics in Retail

28.4.2022 11:00:00 EEST | Business Wire | Press release

Share

Brain Corp, an artificial intelligence (AI) company creating transformative core technology in robotics, and Tennant Company, today announced the European demonstration of Inventory Scan, a powerful new data capture accessory that will be fitted to Tennant’s autonomous floor scrubbers to autonomously scan and report key detail on in-store inventory.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220428005188/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Brain Corp Demonstrates ‘Inventory Scan’ Technology with Tennant Company at Interclean (Photo: Business Wire)

"By adding Inventory Scan to new or existing robotic scrubber fleets, retailers are immediately able to access critical in-store inventory data in near real-time," said Dave Ross, Vice President of Business Development at Brain Corp. "Knowing where an item is, if it’s in stock, if it’s in the correct location, if the price is accurate, and more allows managers to operate stores with a new level of efficiency while providing optimal shopping experiences for their customers. Based on the success we’ve seen in the US with the technology, we are excited to get feedback from those in the European market.”

Utilizing a first-of-its-kind, multi-purpose design, the powerful new scanning accessory will be fitted to Tennant’s floor scrubbers powered by Brain Corp’s BrainOS autonomy software platform. The new, cloud-connected Inventory Scan tower is able to capture data as it moves autonomously around the store. Reports are then delivered to the store managers, providing numerous insights including: verification of pricing accuracy, planogram compliance, product stock levels and product localization. Each function negates the need for time-consuming and potentially inaccurate manual processes, which often lead to lost revenue opportunities, waste caused by overordering and not enough attention given to shoppers.

“The new integrated inventory analytics accessory is filling a much-needed AI and data process gap for retailers,” said Maggie Koester, Global Product Manager at Tennant Company. “What makes this solution compelling is the ability to integrate with retailers’ inventory management systems utilizing their existing floor scrubbers. By adding data collection functionality to these machines, we are dramatically improving how stores operate. Inventory Scan allows retailers to be more efficient and effective by reducing the disruption of labor-intensive manual approaches. Our vision is that data collection and floor care become fully automated so our customers can focus on managing their businesses.”

Interclean 2022 to Host the Unveiling of the Technology in Amsterdam

Inventory Scan will have its European introduction on May 10-13, 2022 at the RAI Centre in Amsterdam, on Brain Corp stand - Hall 7, Booth 108.

"This new product marks the beginning of realizing the next phase in our company's vision and continued growth in Europe as well as the US," said Dr. Eugene Izhikevich, CEO of Brain Corp. "We are actively taking BrainOS-powered robots from primarily task-oriented machines to in-store data acquisition platforms. This delivers critical insights and this will add significant ROI for European retailers as we continue to expand our activity in Europe and beyond."

Brain Corp Sees 100% Year-on-year Growth in European Countries Deploying BrainOS-powered Robots

Partnering with many of the world’s leading OEMs (Original Equipment Manufacturers) including Minuteman, Karcher, Nilfisk and Tennant, autonomous robotic scrubbers, powered by Brain Corp’s AI operating system BrainOS®, are now operational across multiple sectors in 16 European countries.

New countries seeing robotic deployments include Belgium, Denmark, Finland, Luxembourg, Norway and Switzerland. Countries implementing the largest numbers of autonomous robots include France, Spain, Portugal, Italy, Germany, the UK, and the Netherlands.

“There’s no doubt that we’re starting to see the tipping point where the integration of robotics with human teams has gone beyond a novelty and become a practical solution for maintaining sustainable operations,” said Michel Spruijt, SVP International Business at Brain Corp. “We’re seeing significant increases in demand across multiple industry sectors which have been impacted most severely by labor shortages and increased operational strain as a result of the pandemic. Autonomous robotics have proven themselves to be a very effective and welcome solution to these growing problems.”

In 2021, the BrainOS®-powered fleet of autonomous mobile robots hit a major milestone of 500 million square feet covered (46.45 million square meters) autonomously in Europe. In total, over 46,000 hours were given back to workers during the year with the most significant growth coming within retail, logistics, and warehousing sectors.

About Brain Corp

Brain Corp is the global leader in robotic AI software that powers the largest fleet of autonomous mobile robots (AMRs) operating in commercial public spaces. Global OEM partners use the company’s cloud-connected platform, BrainOS®, to create scalable, self-driving robots that are used by end customers to clean floors, move inventory, and sense environmental data - turning manual operations into automated workflows. Fortune 500 brands across multiple verticals benefit from the growing portfolio of BrainOS®-powered robots and our industry-leading privacy, safety and efficiency tools that make managing and scaling automation easier. Brain Corp currently powers more than 20,000 AMRs, representing the largest fleet of its kind in the world.

For more information, visit www.braincorp.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Josh Stanbury | josh@sjspr.co | 416-628-7441

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye